|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2A
|
|
pubmed:dateCreated |
1998-6-18
|
|
pubmed:abstractText |
Anthracyclines are the first line antitumor agents against breast cancer, and P-glycoprotein (Pgp) is thought to be the main resistance mechanism against these agents. We have evaluated the chemosensitivity of fresh surgical specimens of breast cancer and compared them with their Pgp-expression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
967-72
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9615748-Antibiotics, Antineoplastic,
pubmed-meshheading:9615748-Breast Neoplasms,
pubmed-meshheading:9615748-Doxorubicin,
pubmed-meshheading:9615748-Drug Resistance, Neoplasm,
pubmed-meshheading:9615748-Epirubicin,
pubmed-meshheading:9615748-Female,
pubmed-meshheading:9615748-Humans,
pubmed-meshheading:9615748-P-Glycoprotein,
pubmed-meshheading:9615748-Tumor Cells, Cultured
|
|
pubmed:articleTitle |
Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.
|
|
pubmed:affiliation |
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan. tkubota@mc.med.keio.ac.jp
|
|
pubmed:publicationType |
Journal Article
|
